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Executive summary
Overview
Payment by Results is predicated on the assumption that patients allocated to the same Healthcare
Resource Group (HRG) are equally costly to treat. This may be untrue for some patients, such as
those who receive specialised care or who are transferred between hospitals. We assess whether
and by how much such patients have higher costs than those allocated to the same HRG. Hospitals
that treat such patients might be paid a top-up to the HRG tariff to reflect these higher costs.
Data and methods
We combine Hospital Episode Statistics data for all NHS patients treated in England during 2009/10
with cost data reported by all English hospitals. Our analytical sample consists of almost 13 million
patients (provider spells), of whom 1.5 million received some form of specialised care and 620,000
were transferred.
We estimate econometric models to explore why costs vary from among patients. Our explanatory
variables include: (i) the type of specialised care received, if any; (ii) whether or not the patient was
transferred between hospitals; (iii) a range of other patient characteristics; and (iv) the hospital in
which the patient was treated. We perform a range of sensitivity analyses.
Additional costs of specialist care
In general, results are stable between 2008/9 and 2009/10 and are consistent across model
specifications. The main points are of note:
x Sixteen of the specialised markers are insignificant, meaning that patients that receive these
types of specialised care do not have significantly higher costs than other patients allocated to
the same HRG.
x For five of the markers, patients who received this type of specialised care had higher costs
than those allocated to the same HRG who did not. The numbers of patients and the
percentage increase in costs associated with specialised care are:
x cancer (n=11,907, 24%)
x infectious disease (n=2,246, 37%)
x cystic fibrosis (n=101,770, 33%)
x colorectal (n=7,355, 11%)
x children (n=131,657, 20%).
x Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases,
orthopaedics) that were significant (p<0.01) in 2008/9, are either less significant (p<0.05) or
insignificant in 2009/10. This appears to be due primarily to greater polarisation among
providers in their reported costs.
x Results for the pain management specialised marker differ markedly from one year to the
next. This is related to the increase in the number of patients defined as having this
specialised marker and to changes in their cost distribution.
Patient transfers
We find that patients who were transferred between hospitals have significantly higher costs than
those who do not. A reimbursement policy based on this evidence would have to consider the
practical implications of redistributing resources across hospitals to reflect patient flows and any
consequent changes to hospital behaviour.
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1. Introduction
We were commissioned by the Department of Health’s Payment by Results (PbR) team to use
2009/10 data update the analysis we performed using 2008/9 data to estimate the marginal costs of
providing specialised care (Daidone and Street, 2011). The objectives of the original work were to
investigate:
1. Whether the costs associated with specialised activity are significantly different from non-
specialised activity within the same HRG;
2. Whether any differences in costs between specialised and non-specialised activity are
due to differences in productive efficiency.
The objective of the update is:
1. To see whether the results obtained on the 2008-09 data are robust to 2009-10 data.
2. To investigate whether there is a case for differentiating payment on the basis of marginal
cost differences arising when patients transferred between providers.
In the next section we describe various data issues, including how patients are identified as having
received specialised care, how proxy patient-level costs are linked to HES records, and how the
analytical sample is determined. In section three, we summarise the estimation models used to
assess the marginal costs associated with receipt of specialised care and whether or not the patient
was transferred between providers. Following a summary of descriptive statistics (section four),
results are presented in section five for a variety of modelling choices. Estimates for 2009/10 are also
compared to those derived from analysis of 2008/9 data.
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2. Data
There are four major issues regarding the data that need to be addressed:
x How to determine whether or not a patient received specialised care;
x How to assign costs to each patient record in the Hospital Episode Statistics;
x How to determine the cost of a provider spell for those patients who have multiple
consultant episodes;
x How to arrive at an analytical sample.
2.1 Identifying whether a patient received specialised care
Information in each patient’s first diagnostic and procedural fields is examined to ascertain whether or
not specialised care was received. A patient is assigned a specialised care marker if:
x One of the ICD10 in the primary diagnosis field or one of the OPCS codesa in any of the
procedure fields designated in the Specialised Services National Definition Set (SSNDS)
is present in their HES record (an individual might have more than one marker) (NHS
Specialised Services, 2010);
x They were treated at an eligible provider, because non-eligible providers should not be
providing specialised services.
Specialised activity may not necessarily be more costly or complex, since the SSNDS defines activity
as specialised if it requires a planning population of over 1 million people, without any specific relation
to resource use.
2.2 Mapping of reference costs to HES records
To assign patient-level costs we follow the cascade procedure implemented with 2008-09 data, where
each episode in HES is linked to the reference cost database based on: i) the hospital in which the
patient is treated, ii) the HRG where the patient is categorized, iii) the type of admission – day
case/elective/non-elective, and iv) the type of specialty. Further for elective and non-elective cases,
when the length of stay goes beyond HRG specific trimpoints, we add the hospital’s excess per diem
cost for each additional day.
The matching between HES and RC databases has slightly improved with respect to the previous
year's analysis. This is driven mainly by ensuring consistent coding of specialty in the HES and
Reference Cost data by Great Ormond Street Hospital. This allowed a move from a 10% to 90%
match of this provider’s data.
2.3 Assessing the cost of provider spells
Each observation in HES comprises a Finished Consultant Episode (FCE), measuring the time the
patient spends under the care of a particular consultant. As in 2008-09, 91% of patients remain under
the care of a single consultant during their entire hospital stay. The remainder are cared for by more
than one consultant, most usually because they are transferred from one specialty to another. We
track the consultant episodes pertaining to each individual patient, allowing us to construct a provider
spell for each patient, measuring the time from admission to discharge.
Multi-episode spells are likely to be more costly than single-episode spells, but there is no agreed
method for determining the additional cost. In our previous report we found that estimation results
were not sensitive to whether the cost of multi-episode spells was based on the Sum, Maximum or
First of the costs of the constituent FCEs. Consequently, in the analysis that follows, the cost of a
provider spell is calculated as the Sum of the cost of each FCE comprising the patient’s spell in
hospital.
a ICD10: International Statistical Classification of Diseases and Related Health Problems 10th Revision; OPCS: Office for
Population Censuses and Surveys Classification of Surgical Operations and Procedures
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Irrespective of how costs are defined, patients that receive specialised care appear to have higher
costs than those who do not, as can be seen in Table 1. The questions then are:
x Do cost differentials vary according to the particular type of specialised care that is
provided?
x Are these higher costs due solely to the receipt of specialised care or are they (at least
partially) related to the hospital in which care was provided?
Table 1: Mean (SD) costs by type of activity
2.4 Selection of the analytical sample
From an initial sample of 18.1m HES episodes, our analytical sample is reduced to 14.5m episodes
(and 12.9m spells) for the following reasons:
x We consider only those patients treated in NHS acute hospitals. Hence, patients treated
in mental health, ambulance and primary care trusts and private providers are excluded;
x Duplicate HES records, those showing data inconsistencies and those missing key fields
(eg epistart or epiend) are dropped;
x Some observations are excluded either because the reference costs for some hospitals
could not be matched to HES records, because of miscoding of one of the variables used
for mapping as described in section 2.2 (this is especially so for some renal dialysis,
mental health, cystic fibrosis records); or they are unbundled services; or they are
excluded from reference costs (eg intermediate care, well babies);b
x We excluded those episodes with a length of stay in excess of 365 days.
In Table 2 we report how we reduced the full HES dataset to our analytical sample. Improvements in
coding of data have allowed us to retain more of the data than in the previous years, with 80% of the
full set of HES observations included in the 2009/10 analysis, up from 78% in the previous year.
b See Department of Health (2009,2010)
NOT SPEC SPEC TOT NOT SPEC SPEC TOT
Sum 1,385 1,884 1,436 1,452 2,057 1,521
(2,079) (3,790) (2,320) (2371) (4054) ( 2625)
Max 1,219 1,673 1,265 1,272 1,854 1,338
(1,730) (3,210) (1,940) (1987) (3536) (2226)
Epi1 1,142 1,540 1,183 1,189 1,727 1,251
(1,587) (2,929) (1,777) (1825) 3282) (2051)
2008-2009 2009-2010
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Table 2: Eligibility and selection criterion
In Table 11 (see appendix) we provide details for each provider under the following columns:
x Totactivity: the total number of episodes reported in HES after eliminating duplicates and
inconsistencies.
x Norefcost: the number of provider episodes with unmatched costs.
x Finalepi and finalspell: the number of episodes and spells used for the econometric
analysis.
x %MISS and %SPEC: the percentage of missing episodes and the percentage of
episodes with specialised care markers.
Step # episodes
# episodes
dropped # episodes
# episodes
dropped
Starting observations 17,411,542 18,126,831
Acute care trusts only 425,179 470,272
16,986,363 17,656,559
Duplicates and inconsistent coding 852,326 908,904
16,134,037 16,747,655
Unmatched reference cost 2,502,599 2,189,667
13,631,438 14,557,988
Unmatched trimpoint and excess bed days
or zero cost per day 57,678 31,451
Total episodes 13,573,760 3,837,782 14,526,537 3,600,294
Total spells 12,154,599 12,971,384
2008/9 2009/10
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3. Estimation models
3.1 Estimating the additional costs of specialised care
As in our previous report (Daidone and Street, 2011), we define our dependent variable as the
patient’s standardised cost ݕ௜௞ = ܿ௜௛௞ Ƹܿ௛ൗ where ܿ௜௛௞ is the cost of patient i in HRG h in hospital k andƸܿ௛ is the national average cost of all patients allocated to HRG h.
If no account is taken of the possibility that costs may be partly related to the hospital in which care is
provided, the marginal costs associated with receipt of specialised care are estimated by regressing
each patient’s standardised cost against the set (n=1…N) of specialised care markers (S) indicating
the type of specialised care received (if any). The model takes the form:ݕ௜ ൌן ൅ ? ߚ௡ܵ௡௜ ൅ ߝ௜ே௡ୀଵ (EQ1)
where ߚ are the parameters to be estimated: if positive and significant, a patient with the specialist
care marker has higher costs than do other patients allocated to the same HRG. ߝ௜ captures random
error.
As we have previously argued, this model fails to recognise that costs may be driven partly by the
hospital in which the patient is treated. This can be examined by specifying a hierarchical model of the
form:ݕ௜௞ ൌן ൅ ? ߚ௡ܵ௡௜௞ ൅ ݑ௞ ൅ ݒ௜௞ே௡ୀଵ (EQ2)
This is a multi-level model that recognises that patients (i=1…I) are clustered within hospitals
(k=1…K). ݑ௞ is the hospital random effect: patients treated in hospitals with higher effects have
higher costs than those treated elsewhere. ݒ௜௞ captures random measurement error. We argue that
this is the preferred model on which top-up payments should be made as it identifies the additional
costs associated with receipt of specialised care, after controlling for the influence on costs of the
hospital where treatment was provided.
The models are estimated using both ordinary least squares (OLS) and as a generalised linear model
(GLM), and results are shown for both specifications.
3.2 Sensitivity analyses
We consider the sensitivity of estimates derived from applying equation 2 to:
x Analysing costs in their original form;
x Exclusion from the analysis of patients in HRGs in which everyone receives specialised
care; and
x Dropping the requirement that specialised care is defined as being provided in eligible
providers only.
Costs in original units
As an extension to the previous year’s analysis, we now explore results when costs are not
standardised to the national average. This involves incorporating additional explanatory variables that
capture information about the HRG to which each patient is allocated. In this way we still account for
the HRG to which patients are allocated by incorporating two additional variables, namely Ƹܿ௛ the
national average cost of all patients allocated to HRG h and ǁܿ௛ the standard deviation in cost of all
patients allocated to HRG h. This model does not risk the possibility of endogeneity that occurs when
the independent variable is correlated with the error term. The model is specified as:ܿ௜௞ ൌן ൅ߜଵ Ƹܿ௛ ൅ ߜଶ ǁܿ௛ + ? ߚ௡ܵ௡௜௞ ൅ ݑ௞ ൅ ݒ௜௞ே௡ୀଵ (EQ3)
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Fully specialised HRGs
The construction of some HRGs means that everyone allocated to them receives specialised care.
This is because the HRG itself is defined using the ICD or OPCS codes that are also used as
indicators of specialised care. Conversely, some HRGs contain no patients that received specialised
care. The HRGs where the former situation occurs are listed in Table 10 in the appendix.
Estimates might be biased by including in the analysis HRGs exclusively populated by patients who
did receive specialised services. This is because for these HRGs there is no comparative reference
group of patients allocated to the HRG who did not receive specialised care. This makes it impossible
to calculate the differential costs associated with receipt of specialised care for patients allocated to
these HRGs. The extent to which this introduces bias to the estimates of the specialised care marker
depends on how representative patients allocated to these fully specialised HRGs are of all patients
who receive the particular type of specialised care in question.
Dropping patients in those HRGs in which everyone is identified as having received specialised care
and those HRGs in which no-one is identified as having received specialised care reduces the
analytical sample by 1.9% (256,861 spells).
Eligible providers
Some hospitals are or have been designated by the Department of Health as eligible for top-up
payments for some specialised services. As would be expected, hospitals which are or have been
eligible for top-ups now or in the past undertake more specialised spells than do other hospitals.
As described in section 2.1, a patient is defined as receiving specialised care if one of the SSNDS
ICD10 or OPCS codes was present in their medical record and they were treated at an eligible
provider. We assess the sensitivity of results to relaxation of the condition that specialised services
have to be delivered by eligible providers, so that the marker is assigned on the basis of the ICD10 or
OPCS codes alone.
3.3 Estimating the additional costs of being transferred between hospitals
We also assess whether patients who are transferred between institutions have higher costs than
other patients. This involves adding a vector of additional patient characteristics to equation 1, among
which are dummy variables indicating the type of transfer experienced by the patient, if any. The
model is specified as:ݕ௜௞ ൌן ൅ ? ߚ௡ܵ௡௜௞ + ? ߛ௠ܺ௠௜௞ ൅ ݑ௞ +ெ௠ୀଵ ݒ௜௞ே௡ୀଵ (EQ4)
where X is the set (m=1…M) of patient characteristics and ߛ is the vector of parameters to be
estimated. If positive and significant, patients with the particular characteristics have higher costs than
those who do not.
Among this set of variables are four which describe the type of transfer, if one took place. Patients
admitted as transfers are coded 51, 52 and 53 in the admission source field of their HES record;
analogously, those transferred from hospital to other institutions are coded 51, 52 and 53 in the
discharge destination field of their HES record (NHS Information Centre, 2011). We define four
dummy variables:
x Transfer from an eligible provider, whereby the patient was admitted to hospital having been
transferred from a provider that is eligible for specialised payments (tr_in_el);
x Transfer from a non-eligible provider, whereby the patient was admitted to hospital having
been transferred from a provider that is not eligible for specialised payments (tr_in_nonel);
x Transfer to an eligible provider, whereby the patient is transferred to a provider that is eligible
for specialised payments (tr_out_el);
x Transfer to a non-eligible provider, whereby the patient is transferred to a provider that is not
eligible for specialised payments (tr_out_nonel).
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4. Descriptive statistics
In 2009/10, for approximately 1.5m (11.4%) of patients it was indicated that some kind of specialised
care was delivered as part of the treatment package. Table 3 reports the number of patients with
particular conditions who receive specialised services and are included in the analysis. For a few
specialised services, provision has declined compared to 2008/9 – notably cancer (-2,000), liver (-2,600)
and respiratory (-3,500). For others, more patients received specialised care than in the previous
year. Most noticeable were the increases for renal (+150,000), cystic fibrosis (+10,000), cleft lip
(+15,000) and children (+27,000). For children, much of the increase is due to inclusion of a greater
proportion of data from Great Ormond Street. For the vast majority of patients, just one specialised
service was delivered but more than 35,000 patients received more than one specialised service.
Table 3: Number of patients receiving specialised services for whom costs are available
Service 2008/9 2009/10 Service 2008/9 2009/10
Cancer 14,035 11,907 Dermatology 10,790 12,298
BMT 1,050 364 Rheumatology 358 338
Haemophilia 146 153 Endocrinology 7,028 7,306
Women 22,551 24,389 Respiratory 71,824 68,374
Spinal 2,167 2,507 Vascular diseases 801 1,215
Neurosciences 23,848 26,204 Pain Management 753 1,266
Cystic fibrosis 91,868 101,770 Ear surgery 1,704 1,655
Renal 360,957 510,847 Colorectal 6,838 7,355
Intestinal failure 2,380 2,246 Orthopaedic 3,671 4,207
Cardiology 89,127 90,381 Morbid obesity 7,905 11,458
Cleft lip 222,939 238,141 Metabolic disorders 3,182 3,236
Infectious diseases 2,203 2,039 Ophthalmology 6,345 7,006
Liver 14,807 12,244 Haemoglobinopathy 146,403 159,788
Children 104,764 131,657 More than 1 service 32,311 35,972
In Table 4 we provide some descriptive statistics of the explanatory variables used to describe
patient characteristics (ie Xm in equation 4). Patients receiving specialised services are more likely to
be male, younger (probably mainly because infants are more likely to require specialised care, 16% of
them at birth), and to have been transferred between hospitals. Notably, there are no major
differences in the proportions of patients with each particular characteristic between the two years of
data. Variable definitions are provided in Table 14 in the appendix.
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Table 4: Descriptive statistics of explanatory variables (mean above, st.dev. below)
NOT SPEC SPEC TOT NOT SPEC SPEC TOT
female1 0.574 0.445 0.56 0.577 0.442 0.558
(0.495) (0.497) (0.496) (0.495) (0.497) (0.497)
age 51.61 49.94 51.44 51.56 50.42 51.43
(24.24) (25.7) (24.4) (24.49) (25.76) (24.64)
urban1 0.818 0.817 0.818 0.818 0.827 0.819
(0.386) (0.387) (0.386) (0.386) (0.378) (0.385)
episodes 1.118 1.108 1.117 1.122 1.102 1.12
(0.426) (0.545) (0.440) (0.442) (0.546) (0.455)
emerg 0.383 0.159 0.36 0.396 0.145 0.367
(0.486) (0.366) (0.48) (0.489) (0.352) (0.482)
die 0.0155 0.0181 0.0158 0.0143 0.0153 0.0145
(0.124) (0.133) (0.125) (0.119) (0.123) (0.119)
tr_in_el 0.0000394 0.00016 5.20E-05 0.0000493 0.000158 0.0000617
(0.00628) (0.0128) (0.0072) (0.00702) (0.0126) (0.00785)
tr_in_nonel 0.0265 0.0414 0.028 0.03 0.0376 0.0308
(0.161) (0.199) (0.165) (0.17) (0.19) (0.173)
tr_out_el 0.00501 0.00491 0.005 0.00532 0.00498 0.00528
(0.0706) (0.0699) (0.0705) (0.0728) (0.0704) (0.0725)
tr_out_nonel 0.0113 0.0135 0.0116 0.0115 0.0128 0.0117
(0.106) (0.115) (0.107) (0.107) (0.112) (0.107)
pregnancy 0.104 0.00528 0.0941 0.107 0.0039 0.0951
(0.306) (0.0725) (0.292) (0.309) (0.0623) (0.293)
drug 0.00324 0.00203 0.00312 0.00355 0.00211 0.00339
(0.0568) (0.045) (0.056) (0.0595) (0.0459) (0.0581)
alcohol 0.017 0.00732 0.016 0.0198 0.00692 0.0183
(0.129) (0.0852) (0.125) (0.139) (0.0829) (0.134)
smoke 0.0369 0.0348 0.0367 0.0468 0.0367 0.0456
(0.189) (0.183) (0.188) (0.211) (0.188) (0.209)
obesity 0.0072 0.014 0.00791 0.00993 0.0154 0.0106
(0.0845) (0.118) (0.089) (0.0991) (0.123) (0.102)
allergy 0.0276 0.0191 0.0267 0.0328 0.0201 0.0313
(0.164) (0.137) (0.161) (0.178) (0.14) (0.174)
diabetes 0.0785 0.0626 0.0769 0.0869 0.0603 0.0838
(0.269) (0.242) (0.266) (0.282) (0.238) (0.277)
hypertens 0.171 0.121 0.165 0.192 0.117 0.184
(0.376) (0.326) (0.372) (0.394) (0.322) (0.387)
haemorr 0.00393 0.00899 0.00445 0.00452 0.00781 0.00489
(0.0626) (0.0944) (0.067) (0.0671) (0.088) (0.0698)
histdis 0.108 0.0866 0.106 0.124 0.0862 0.119
(90.31) (0.281) (0.307) (0.329) (0.281) (0.324)
riskfact 0.00729 0.00265 0.00681 0.00907 0.0032 0.0084
(0.0851) (0.0514) (0.082) (0.0948) (0.0565) (0.0913)
congmalf 0.0113 0.0487 0.0151 0.0124 0.0522 0.0169
(0.106) (0.215) (0.122) (0.111) (0.222) (0.129)
risk_phys 0.000643 0.00119 0.0007 0.000675 0.00125 0.000741
(0.0254) (0.0345) (0.027) (0.026) (0.0354) (0.0272)
risk_psysoc 0.00384 0.00157 0.00361 0.00447 0.00148 0.00413
(0.0619) (0.0395) (0.060) (0.0667) (0.0384) (0.0641)
2009/102008/9
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5. Results
5.1 Additional costs of specialist care
We have estimated various equations and explored the sensitivity of estimates to a range of
modelling choices. The cost of a provider spell is calculated as the sum of the cost of the constituent
episodes and each patient is assigned a specialist marker if one of the SSNDS ICD10 or OPCS
codes appears in their record and they were treated at an eligible provider. In this section we focus on
the estimates associated with the specialised markers. Rather than reporting the coefficients, we
report the predicted percentage increase in costs for specialised services calculated as described in
our earlier report (Daidone and Street, 2011). The specialised markers where estimates are
statistically significant appear in bold if p<0.01 and underlined if p<0.05.
Table 5: Equations 1 and 2 on standardised dependent variable
Notes: Bold figures 1% significant, underlined figures 5%
Table 5 shows estimates of additional costs associated with receipt of specialised care from applying
equations 1 and 2, estimated using OLS and GLM models and for the two years of data. The
estimates are not sensitive to the choice of OLS and GLM. As to year-on-year comparisons,
estimates are very similar in most of the cases, both in terms of magnitude and statistical significance.
This is despite the fact that the reference populations have changed, as they are composed of two
entirely different sets of patients.
Focussing on equation 2, the main points are the following:
x Sixteen of the specialised markers are insignificant, across both the OLS and GLM
specifications and for the two years of data. This means that patients that receive
specialised care of the nature indicated by the specialised marker do not have
significantly higher costs than other patients allocated to the same HRG.
x For five of the markers, patients who received this type of specialised care had higher
costs than those allocated to the same HRG who did not. These markers are cancer,
OLS GLM OLS GLM OLS GLM OLS GLM
Cancer 0.217 0.218 0.307 0.313 0.184 0.185 0.242 0.244
BMT -0.055 -0.035 -0.037 -0.037 -0.105 -0.086 -0.297 -0.222
Haemophilia -0.089 -0.090 -0.132 -0.129 -0.144 -0.142 -0.159 -0.157
Womens -0.003 -0.002 0.063 0.061 -0.019 -0.018 0.046 0.046
Spinal 0.323 0.336 0.140 0.154 0.276 0.279 -0.115 -0.084
Neurosciences 0.279 0.276 0.280 0.275 0.229 0.225 0.171 0.171
Cystic Fibrosis 0.397 0.394 0.357 0.354 0.379 0.380 0.331 0.335
Renal -0.112 -0.114 0.228 0.230 -0.112 -0.112 0.175 0.180
Intestinal Failure -0.007 -0.004 -0.003 -0.002 0.002 0.004 0.008 0.009
Cardiology 0.138 0.138 0.118 0.119 0.001 0.000 0.007 0.011
CleftLip -0.017 -0.018 0.034 0.035 -0.042 -0.044 0.022 0.023
Infectious Diseaes 0.264 0.240 0.408 0.393 0.213 0.189 0.379 0.372
Liver 0.098 0.099 0.125 0.128 0.075 0.076 0.003 0.018
Children 0.280 0.278 0.301 0.302 0.200 0.193 0.215 0.204
Dermatology 0.009 0.009 -0.003 -0.007 -0.009 -0.009 -0.019 -0.022
Rheumatology 0.183 0.184 0.331 0.337 0.130 0.130 0.102 0.089
Endocrinology 0.045 0.041 0.061 0.057 -0.007 -0.010 -0.014 -0.011
Respiratory 0.046 0.041 0.078 0.072 -0.038 -0.041 0.001 -0.002
Vascular Diseases 0.246 0.241 0.343 0.323 0.211 0.203 0.218 0.198
Pain Management 0.188 0.157 2.255 2.283 0.190 0.169 2.129 2.101
EarSurgery 0.057 0.058 0.082 0.086 -0.001 -0.001 -0.111 -0.078
Colorectal 0.214 0.214 0.129 0.129 0.211 0.214 0.112 0.114
Orthopaedic 0.244 0.238 0.164 0.161 0.213 0.207 0.004 0.011
Morbid Obesity -0.027 -0.027 -0.068 -0.068 -0.008 -0.007 -0.068 -0.071
Metabolic Disorders 0.022 0.011 0.427 0.430 -0.016 -0.021 0.312 0.295
Ophthalmology 0.080 0.076 0.074 0.069 0.057 0.055 0.057 0.053
Haemoglobinopathy 0.013 0.009 0.065 0.066 0.003 0.000 0.052 0.056
2008-2009 2009-2010
Equation 1 Equation 2
2008-2009 2009-2010
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cystic fibrosis, infectious disease, children and colorectal. The significance (p<0.01) of
these markers holds across specifications and over time. The estimates of the amount by
which costs are higher do vary from one year to the next though. The estimates are
higher for cancer (from 18% to 24%) and infectious disease (21% to 37%) and are lower
for cystic fibrosis (38% to 33%) and colorectal (21% to 11%). The estimates are
unchanged for children’s specialised services (20%).
x Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases,
orthopaedics) that were significant in 2008/9, are no longer significant at p<0.01, though
results remain significant at p<0.05 for neurosciences and vascular diseases (under the
GLM specification). Compare these estimates to those derived from applying equation 1.
We find that, with the exception of the marker for spinal services, the other four
specialised markers are significant in 2009/10 provided that no account is taken of the
hospital in which patients are treated. This suggests greater polarisation in 2009/10
among providers in the costs of treating patients allocated to the HRGs in which these
specialised markers tend to appear.
x In Table 6 we report the number of hospitals where mean costs decrease or increase by
more than 0.5 standard deviations of the mean across all patients in 2009/10. Polarisation
is evident if there are large reductions in cost for some providers and large increases for
others.
x Consider first the specialised care for cystic fibrosis. For these services, no hospital
reported large decreases in cost, and few very experienced increases. The estimates
reported in Table 5 for this specialist marker are quite stable across specifications and
over time.
x In contrast, Table 6 shows that mean hospital costs changed considerably for a sizeable
large numbers of hospitals providing specialised care in rheumatology, vascular diseases
and orthopaedics. This variance across hospitals is captured by the hospital effect, rather
than by the specialist marker which appears non-significant in Eqn 2 for 2009/10 (Table
5).
x Polarisation in mean costs across hospitals is less extreme for specialised neurosciences
care than for rheumatology, vascular diseases and orthopaedics. Consequently in
2009/10, the coefficient on this specialised marker remains significant in Eqn 2, albeit at a
lower significance level.
x For specialised spinal care, there is little change from one year to the next in the location
and shape of the overall distribution of costs for patients who received this form of
specialised care. In contrast to 2008/9, the non-significance of this marker in 2009/10 is
partly due to changes in costs for patients who did not receive specialised spinal care
who are allocated to the same HRGs as patients who did and partly due to the handful of
hospitals (5-6%) for which mean costs changed by +/- 0.5 standard deviations of the
overall mean.
Table 6: Number (%) of hospitals in which mean costs vary from 2008/9 and 2009/10 by +/- 0.5SD of the
underlying distribution
Decrease by <0.5SD Increase by >0.5SD
Cystic fibrosis 0 0% 4 3%
Rheumatology 10 15% 16 25%
Vascular Diseases 9 9% 17 17%
Orthopaedics 14 10% 19 13%
Neurosciences 4 3% 5 3%
Spinal 9 6% 8 5%
x Finally, returning to Table 5, the pain management marker was insignificant in 2008/9 but
is remarkably so in 2009/10. This is explained partly by the 50% increase in the number
of patients with this specialised marker Table 3) and by changes in the location and
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shape of the cost distribution for these patients, the lower peak and longer tail in 2009/10
being most notable (figure 1). These changes are reflected in the dramatic change
between the two years in the estimated coefficients associated with this specialised
marker.
Figure 1: Kernel density estimation of specialised services costs
5.2 Sensitivity analyses
The OLS estimates for 2009/10 reported in Table 5 are reproduced in column 1 in Table 7 alongside
estimates from the sensitivity analyses, namely:
x Analysing costs in their original form (EQ3, column 2);
x Exclusion from the analysis of patients in HRGs in which everyone receives specialised
care (column 3); and
x Dropping the requirement that specialised care is defined as being provided in eligible
providers only (column 4).
The main points of note are:
x For the majority of specialised care markers, the estimates are unchanged across all
forms of sensitivity analysis. Twenty of the markers that were insignificant (p>0.01) under
the original specification remain so under the three alternatives.
x The receipt of specialised cancer care is consistently estimated to increase costs by 24%.
x The magnitude and (sometimes) significance of the estimates for four of the markers are
sensitive to whether costs are standardised (EQ2, column 1) or estimated in original units
(EQ3, column 2). Estimates are higher if applying EQ3 for neurosciences (17% to 32%),
cystic fibrosis (33% to 61%) and infectious diseases (38% to 49%). For pain
management, the cost differential no longer appears significant.
x Results are not sensitive to dropping HRGs in which everyone is identified as having
received specialised care and those HRGs in which no-one is identified as having
received specialised care. The signs and, where significant, the magnitudes of the
estimates reported in columns 1 and 3 are virtually identical. Interestingly, this is true
even for cardiology, where a high proportion of HRGs are populated entirely by patients
defined as having received specialised care (Table 10 in Appendix).
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Table 7: Sensitivity analysis, equation 2 - 2009/2010
2009-2010
(1) (2) (3) (4)
Standardised
Dependent
Variable –
equation 2
Raw Dependent
Variable - equation
3
100% fully
specialized
HRGs dropped -
equation 2
No eligibility
requirements
- equation 2
Cancer 0.242 0.238 0.240 0.242
BMT -0.297 -0.366 -0.347 -0.296
Haemophilia -0.159 -0.120 -0.162 -0.160
Womens 0.046 -0.005 0.046 0.046
Spinal -0.115 0.138 -0.120 -0.077
Neurosciences 0.171 0.315 0.166 0.151
Cystic Fibrosis 0.331 0.611 0.339 0.330
Renal 0.175 0.054 0.176 0.174
Intestinal Failure 0.008 -0.007 0.009 0.008
Cardiology 0.007 0.065 0.008 0.016
CleftLip 0.022 0.014 0.022 0.021
Infectious Diseases 0.379 0.491 0.379 0.379
Liver 0.003 0.126 -0.004 0.011
Children 0.215 0.211 0.223 0.102
Dermatology -0.019 0.002 -0.024 -0.021
Rheumatology 0.102 0.149 0.102 0.101
Endocrinology -0.014 0.028 -0.016 -0.014
Respiratory 0.001 0.089 0.014 0.029
Vascular Diseases 0.218 0.790 0.276 0.214
Pain Management 2.129 1.181 2.127 2.125
EarSurgery -0.111 0.141 -0.036 -0.113
Colorectal 0.112 0.127 0.112 0.111
Orthopaedic 0.004 0.112 0.003 0.003
Morbid Obesity -0.068 -0.259 -0.071 -0.069
Metabolic Disorders 0.312 -0.076 0.306 0.303
Ophthalmology 0.057 0.030 0.058 0.056
Haemoglobinopathy 0.052 0.053 0.053 0.053
Notes: Bold figures 1% significant, underlined figures 5%
x In the fourth column of Table 7 we present the effects for the specialist markers followed
by the effects generated after relaxing the condition that specialised services have to be
delivered only by eligible providers. Again comparing these estimates with those in
column 1, the results are generally not sensitive to whether or not specialised care is
defined as being confined to eligible providers.
x There is, however, one notable exception: the cost increase associated with specialised
children services is now estimated to amount to just 10%, rather than 22%. This would
suggest that the cost of specialised children’s care is lower in non-eligible than eligible
providers.
5.3 Transfers between providers
Providers have raised the question of whether patients who are transferred between providers should
receive a top-up and, if so, what value the top-up should take. In answering this we first evaluate how
many patients are transferred and the marginal cost consequences of being transferred.
Table 8 provides details of the number of patients who were transferred into or from other institutions,
according to whether or not their hospital was eligible for specialised top-ups and to whether or not
they received specialised care. The proportion of patients who were transferred into hospital
increased from 2.8% in 2008/9 to 3.1% in 2009/10. The proportion of patients transferred to other
providers was 1.7% in both years.
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Table 8: Number of spells with patients transferred
Number of spells
2008-2009 2009-2010
Transfer type Not Spec Spec Tot Not Spec Spec Tot
From eligible 445 216 661 567 233 800
From non-eligible 289,139 51,800 340,939 344,445 55,457 399,902
To eligible 54,609 6,153 60,762 61,203 7,345 68,548
To non-eligible 123,722 16,879 140,601 132,290 18,896 151,186
Those who were transferred have significantly higher costs than those who do not (Table 9). Patients
transferred from non-eligible providers have costs 24% higher than those who do not (all else equal),
and those transferred to other providers have 11-13% higher costs.
Table 9: Coefficient estimates of transfer variables, equation 4.
Co efficient estimates
2008-2009 2009-2010
From eligible 0.008 -0.061
(0.070) (0.057)
From non-eligible 0.16** 0.235***
(0.071) (0.040)
To eligible 0.14*** 0.132***
(0.016) (0.017)
To non-eligible 0.129*** 0.110***
(0.020) (0.015)
Notes: standard errors in parentheses. *** 1% significant - ** 5% significant
Even though patients who are transferred have higher costs than those who do not, introducing top-
up payments to reflect this might not be straightforward, for two main reasons:
x First, in effect, any payment adjustment should reflect patient flows, with funding being
redistributed from providers that transfer patients elsewhere to providers that admit them.
This would be prohibitively costly to implement on a case-by-case basis, so probably the
redistribution would have to be undertaken centrally and retrospectively.
x Second, payments of this nature might lead to changes in decisions about whether or not
to transfer patients elsewhere. This may be no bad thing, but an evaluation of potential
behavioural change might be required.
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6. Conclusion
In general, results are stable from one year to the next and are consistent across model
specifications. Of note are the following points:
x Sixteen of the specialised markers are insignificant, meaning that patients that receive
these types of specialised care do not have significantly higher costs than other patients
allocated to the same HRG.
x For five of the markers, patients who received this type of specialised care had higher
costs than those allocated to the same HRG who did not. The numbers affected and the
percentage increase in costs associated with each form of specialised care are:
x cancer (n=11,907, 24%)
x infectious disease (n=2,246, 37%)
x cystic fibrosis (n=101,770, 33%)
x colorectal (n=7,355, 11%)
x children (n=131,657, 20%).
x Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases,
orthopaedics) that were significant (p<0.01) in 2008/9, are either less significant (p<0.05)
or insignificant in 2009/10. This appears to be due primarily to greater polarisation among
providers in their reported costs.
x Results for pain management marker differ markedly from one year to the next. This is
related to the increase in the number of patients defined as having this specialised marker
and to changes in the overall distribution of their costs.
We also find that, after controlling for whether or not they receive specialised care and for a range of
other characteristics, patients who were transferred between hospitals have significantly higher costs
than those who do not. This evidence is a necessary but not sufficient condition for introducing top-up
payments for such patients. Any such policy would have to consider the practical implications of
redistributing resources to reflect patient flows and any consequent changes to hospital behaviour
toward patients who might be transferred.
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Appendix
Table 10: Fully specialised HRGs
hrg4 Episodes HRG description
EA14Z 11,467 Coronary Artery Bypass Graft (First Time)
DZ18Z 4,292 Sleeping Disorders Affecting Breathing
EA17Z 3,624 Single Cardiac Valve Procedures
EA51Z 3,170 Coronary Artery Bypass Graft with valve replacement or repair
GC01B 2,742 Liver Failure Disorders without Interventions
LB29B 2,532 Urethra Major Open Procedures 18 years and under
AA28Z 2,432 Motor Neuron Disease
EA16Z 2,403 Coronary Artery Bypass Graft (First Time) with Percutaneous Coronary Intervention, Pacing, EP of RFA
FZ24D 1,351 Major Therapeutic Open or Endoscopic Procedures 18 years and under
EA20Z 1,295 Other Complex Cardiac Surgery and Re-do's
EA19Z 1,087 Single Cardiac Valve Procedures with Percutaneous Coronary Intervention, Pacing, EP or RFA
GC01A 921 Liver Failure Disorders with Interventions
SA26A 857 Peripheral Blood Stem Cell Transplant - Autologous 19 years and over
EA52Z 856 Repair or replacement of more than one heart valve
CZ26Z 741 Bone Anchored Hearing Aids
JC19U 707 Electrical and other invasive therapy 4 - 18 years and under
LB46Z 693 Live Donation of Kidney
EA26Z 638 Standard Congenital Surgery
CZ25Q 633 Cochlear Implants without CC
LA03A 614 Kidney Transplant 19 years and over from Live donor
SA14Z 494 Plasma Exchanges 2 to 9
LA02A 469 Kidney Transplant 19 years and over from Cadaver Heart beating donor
DZ33Z 433 Hyperbaric Oxygen Treatment
EA23Z 363 Major Complex Congenital Surgery
SA28A 346 Peripheral Blood Stem Cell Transplant - Allogeneic 19 years and older
DZ21G 238 Chronic Obstructive Pulmonary Disease or Bronchitis with NIV without Intubation without CC
LA01A 230 Kidney Transplant 19 years and over from Cadaver non-Heart beating donor
SA19A 229 BoneMarrow Transplant - Autograft 19 years and over
CZ25N 218 Cochlear Implants with CC
HC09Z 174 Intradural Spine Intermediate 2
SA15Z 142 Plasma Exchanges 10 to 19
EA22Z 129 Other Complex Cardiac Surgery with Percutaneous Coronary Intervention, Pacing, EP or RFA
FZ01C 116 Complex Oesophageal Procedures 18 years and under
HC08Z 103 Intradural Spine Major 1
DZ01Z 89 Lung Transplant
SA20A 88 BoneMarrow Transplant - Allogeneic Graft (Sibling) 19 years and over
EA02Z 84 Heart Transplant
EA43Z 81 Implantation of Prosthetic Heart or Ventricular Assist Device
SA26B 50 Peripheral Blood Stem Cell Transplant - Autologous 18 years and under
LA03B 44 Kidney Transplant 18 years and under from Live donor
LA02B 42 Kidney Transplant 18 years and under from Cadaver Heart beating donor
SA28B 31 Peripheral Blood Stem Cell Transplant - Allogeneic 18 years and under
SA20B 30 BoneMarrow Transplant - Allogeneic Graft (Sibling) 18 years and under
SA21B 20 BoneMarrow Transplant - Allogeneic Graft (Volunteer Unrelated Donor) 18 years and under
LA12A 19 Kidney pre-transplantation work-up of recipient 19 years and over
SA22A 16 BoneMarrow Transplant - Allogeneic Graft (Cord Blood) 19 years and over
LA11Z 15 Kidney pre-transplantation work-up of live donor
SA16Z 13 Plasma Exchanges 20 ormore
WA01Y 12 Manifestations of HIV/AIDS without CC
SA19B 11 BoneMarrow Transplant - Autograft 18 years and under
WA01W 10 Manifestations of HIV/AIDS with CC
SA22B 10 BoneMarrow Transplant - Allogeneic Graft (Cord Blood) 18 years and under
GA01B 9 Hepatobiliary Transplant 2 to 17 years
GA01A 6 Hepatobiliary Transplant 1 year and under
LA10Z 5 Live Kidney donor screening
DZ46Z 4 Respiratory Muscle Strength Studies
LA01B 3 Kidney Transplant 18 years and under from Cadaver non-Heart beating donor
SA27A 2 Peripheral Blood Stem Cell Transplant - Syngeneic 19 years and over
SA23A 2 BoneMarrow Transplant - Allogeneic Graft (Haplo-Identical) 19 years and over
DZ45Z 1 Lung Volume Studies
EA01Z 1 Heart & Lung Transplant
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Table 11: Provider Information
Key: Totactivity: the total number of episodes reported in HES after eliminating duplicates and inconsistencies. Norefcost: the number of provider episodes with unmatched
costs. The two columns finalepi and finalspell represent respectively the number of episodes and spells used for the econometric analysis. %MISS and %SPEC indicate the
percentage of missing episodes and the percentage of episodes with specialised care markers.
procode3 Hospital Name totactivity norefcost finalepi finalspell % MISS % SPEC
RR1 Heart of England NHS Foundation Trust 306,731 23,410 283,258 250,038 7.65 28.04
RHQ Sheffield Teaching Hospitals NHS Foundation Trust 297,715 37,869 259,812 238,867 12.73 44.61
RWE University Hospitals of Leicester NHS Trust 267,803 27,009 240,791 208,738 10.09 11.97
RR8 Leeds Teaching Hospitals NHS Trust 257,225 23,209 232,903 205,721 9.46 13.98
RW6 Pennine Acute Hospitals NHS Trust 245,134 24,616 220,305 197,757 10.13 5.42
RX1 Nottingham University Hospitals NHS Trust 221,639 34,608 186,049 162,883 16.06 13.00
RM1 Norfolk and Norwich University Hospital NHS Trust 217,319 24,134 193,017 169,225 11.18 23.53
RTH Oxford Radcliffe Hospitals NHS Trust 216,582 14,036 202,545 190,223 6.48 36.42
RXN Lancashire Teaching Hospitals NHS Foundation Trust 210,031 34,078 175,816 165,898 16.29 6.40
RTE Gloucestershire Hospitals NHS Foundation Trust 206,097 48,664 157,373 138,514 23.64 4.80
RJE University Hospital of North Staffordshire NHS Trust 202,646 15,084 187,312 167,766 7.57 16.41
RTD The Newcastle Upon Tyne Hospitals NHS Foundation Trust 201,320 31,149 169,545 158,189 15.78 15.07
RJ1 Guy's and St Thomas' NHS Foundation Trust 199,824 11,696 187,820 180,341 6.01 13.36
RVJ North Bristol NHS Trust 188,638 4,860 183,475 171,464 2.74 40.64
RW3 Central Manchester and Manchester Children's University Hospitals NHS Trust 184,726 15,574 169,071 153,979 8.47 40.85
RAL Royal Free Hampstead NHS Trust 183,398 90,998 90,792 81,666 50.49 9.95
RGT Cambridge University Hospitals NHS Foundation Trust 183,327 60,823 122,437 114,937 33.21 13.96
RYJ Imperial College Healthcare NHS Trust 183,307 26,395 156,802 142,066 14.46 13.65
RYQ South London Healthcare NHS Trust 175,337 12,194 162,733 150,014 7.19 4.52
RTG Derby Hospitals NHS Foundation Trust 174,860 18,580 156,269 133,093 10.63 5.61
RWD United Lincolnshire Hospitals NHS Trust 172,582 16,647 155,675 136,247 9.80 4.33
RWA Hull and East Yorkshire Hospitals NHS Trust 171,457 10,070 161,250 138,984 5.95 10.45
RTR South Tees Hospitals NHS Trust 163,455 24,016 139,426 118,578 14.70 10.97
RHU Portsmouth Hospitals NHS Trust 162,693 24,310 137,466 118,261 15.51 6.67
RXF Mid Yorkshire Hospitals NHS Trust 158,609 9,087 149,522 129,702 5.73 4.15
RH8 Royal Devon and Exeter NHS Foundation Trust 157,081 13,214 143,211 120,320 8.83 13.39
RVV East Kent Hospitals NHS Trust 155,994 20,966 132,610 124,896 14.99 5.89
REF Royal Cornwall Hospitals NHS Trust 155,785 15,660 140,087 121,770 10.08 8.41
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procode3 Hospital Name totactivity norefcost finalepi finalspell % MISS % SPEC
RHM Southampton University Hospitals NHS Trust 154,564 14,015 140,390 113,195 9.17 18.51
RF4 Barking, Havering and Redbridge Hospitals NHS Trust 154,117 16,922 137,173 118,376 10.99 5.08
RXK Sandwell and West Birmingham Hospitals NHS Trust 153,787 12,097 141,688 126,597 7.87 4.69
RA7 United Bristol Healthcare NHS Trust 149,437 21,943 126,756 109,364 15.18 20.53
RKB University Hospitals Coventry and Warwickshire NHS Trust 148,717 13,878 134,788 117,514 9.37 9.10
RXR East Lancashire Hospitals NHS Trust 144,248 18,102 126,146 111,334 12.55 3.81
RXP County Durham and Darlington NHS Foundation Trust 139,859 6,820 133,038 118,895 4.88 3.83
RNA Dudley Group of Hospitals NHS Trust 136,450 26,609 109,783 98,713 19.54 8.29
RLN City Hospitals Sunderland NHS Foundation Trust 135,553 18,762 116,791 102,281 13.84 5.76
RTF Northumbria Healthcare NHS Foundation Trust 134,105 14,130 119,945 102,856 10.56 3.81
RM3 Salford Royal NHS Foundation Trust 132,649 48,480 83,871 72,445 36.77 7.30
RHW Royal Berkshire NHS Foundation Trust 132,345 8,801 123,544 120,564 6.65 35.23
RL4 The Royal Wolverhampton Hospitals NHS Trust 131,927 18,392 113,507 102,254 13.96 16.77
RQ6 Royal Liverpool and Broadgreen University Hospitals NHS Trust 131,740 8,985 122,755 107,476 6.82 13.59
RK9 Plymouth Hospitals NHS Trust 131,563 11,210 120,251 106,152 8.60 11.26
RJZ King's College Hospital NHS Foundation Trust 130,211 21,753 101,609 90,596 21.97 25.21
RYR Western Sussex Hospitals NHS Trust 128,301 8,842 119,170 106,965 7.12 4.67
RVL Barnet and Chase Farm Hospitals NHS Trust 126,442 18,341 107,724 95,522 14.80 5.71
RDZ The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust 126,373 23,934 102,236 83,507 19.10 2.87
RXW Shrewsbury and Telford Hospital NHS Trust 125,974 14,871 111,103 99,258 11.80 15.25
RWY Calderdale and Huddersfield NHS Foundation Trust 123,799 10,204 113,429 100,545 8.38 4.26
REM Aintree University Hospitals NHS Foundation Trust 123,542 10,063 113,193 89,699 8.38 23.53
RRK University Hospital Birmingham NHS Foundation Trust 122,971 8,288 114,675 105,630 6.75 36.73
RP5 Doncaster and Bassetlaw Hospitals NHS Foundation Trust 122,479 9,485 112,992 101,020 7.75 4.85
RJ7 St George's Healthcare NHS Trust 118,887 11,285 107,292 103,192 9.75 13.09
RWP Worcestershire Acute Hospitals NHS Trust 118,010 13,047 104,955 97,144 11.06 3.91
RXL Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust 117,989 9,616 107,792 91,881 8.64 9.89
RAE Bradford Teaching Hospitals NHS Foundation Trust 117,687 7,970 109,536 101,829 6.93 5.27
RRV University College London Hospitals NHS Foundation Trust 115,293 14,568 100,554 95,633 12.78 17.06
RBL Wirral University Teaching Hospital NHS Foundation Trust 112,525 8,940 103,560 89,657 7.97 3.52
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procode3 Hospital Name totactivity norefcost finalepi finalspell % MISS % SPEC
RXH Brighton and Sussex University Hospitals NHS Trust 110,739 3,381 107,301 95,393 3.10 10.30
RWH East and North Hertfordshire NHS Trust 110,530 8,755 100,823 89,528 8.78 4.46
RTX University Hospitals of Morecambe Bay NHS Trust 109,052 14,061 94,911 86,381 12.97 4.53
RJL Northern Lincolnshire and Goole Hospitals NHS Foundation Trust 108,267 25,142 83,117 72,775 23.23 5.86
RNJ Barts and The London NHS Trust 107,558 33,715 72,547 71,240 32.55 23.38
RV8 North West London Hospitals NHS Trust 107,009 15,421 91,531 82,549 14.46 4.22
RXC East Sussex Hospitals NHS Trust 106,409 8,207 98,186 89,502 7.73 5.63
RQ8 Mid Essex Hospital Services NHS Trust 106,207 11,146 95,061 84,546 10.49 5.26
RDD Basildon and Thurrock University Hospitals NHS Foundation Trust 105,718 24,582 81,037 69,026 23.35 10.18
RBN St Helens and Knowsley Hospitals NHS Trust 104,510 32,007 72,499 61,916 30.63 2.00
RWF Maidstone and Tunbridge Wells NHS Trust 100,757 12,622 88,135 81,321 12.53 6.00
RVR Epsom and St Helier University Hospitals NHS Trust 99,896 10,984 88,811 78,629 11.10 6.07
RNS Northampton General Hospital NHS Trust 98,636 12,350 86,286 77,805 12.52 6.18
RDE Essex Rivers Healthcare NHS Trust 98,523 19,199 79,098 65,866 19.72 4.11
RAJ Southend University Hospital NHS Foundation Trust 96,533 30,837 65,696 61,164 31.94 4.11
RVW North Tees and Hartlepool NHS Foundation Trust 96,358 8,049 88,309 74,998 8.35 2.66
RXQ Buckinghamshire Hospitals NHS Trust 95,159 8,518 85,872 80,538 9.76 4.76
RDU Frimley Park Hospital NHS Foundation Trust 94,091 7,390 86,699 75,881 7.86 3.86
RGN Peterborough and Stamford Hospitals NHS Foundation Trust 93,019 10,649 82,366 71,552 11.45 5.45
RNL North Cumbria Acute Hospitals NHS Trust 92,816 6,355 86,461 78,268 6.85 7.82
RK5 Sherwood Forest Hospitals NHS Foundation Trust 92,793 43,012 49,745 47,179 46.39 3.45
RGQ Ipswich Hospital NHS Trust 92,126 12,969 79,117 67,677 14.12 5.38
RWJ Stockport NHS Foundation Trust 91,509 12,413 79,083 75,421 13.58 3.51
RWW North Cheshire Hospitals NHS Trust 91,279 5,227 86,052 74,482 5.73 4.26
RRF Wrightington, Wigan and Leigh NHS Trust 90,698 1,346 89,269 77,178 1.58 5.56
RWG West Hertfordshire Hospitals NHS Trust 90,560 4,206 86,030 76,236 5.00 5.58
RM2 University Hospital of South Manchester NHS Foundation Trust 90,239 26,453 63,721 60,013 29.39 13.43
RD7 Heatherwood and Wexham Park Hospitals NHS Foundation Trust 89,430 17,165 72,265 61,416 19.19 5.15
RN3 Swindon and Marlborough NHS Trust 88,792 6,543 82,177 70,710 7.45 5.87
RCB York Hospitals NHS Foundation Trust 87,571 3,498 83,774 73,717 4.34 4.61
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RD3 Poole Hospital NHS Foundation Trust 86,093 9,745 76,325 67,614 11.35 5.67
RC9 Luton and Dunstable Hospital NHS Foundation Trust 85,284 5,719 79,223 67,503 7.11 6.76
RGC Whipps Cross University Hospital NHS Trust 84,498 8,017 76,480 69,458 9.49 5.34
RBA Taunton and Somerset NHS Foundation Trust 84,387 12,017 72,370 65,144 14.24 5.64
RGP James Paget University Hospitals NHS Foundation Trust 84,194 23,244 60,950 53,362 27.61 4.24
RBD Dorset County Hospital NHS Foundation Trust 83,767 6,230 77,537 72,115 7.44 10.31
RBT Mid Cheshire Hospitals NHS Trust 83,383 5,968 76,777 64,959 7.92 2.34
RMC Bolton Hospitals NHS Trust 81,271 3,749 77,397 69,944 4.77 5.03
RPA Medway NHS Trust 78,936 11,955 66,762 59,397 15.42 4.21
RD1 Royal United Hospital Bath NHS Trust 78,089 2,891 75,115 65,188 3.81 6.25
RNQ Kettering General Hospital NHS Trust 78,067 4,100 73,966 65,938 5.25 5.65
RCX The Queen Elizabeth Hospital King's Lynn NHS Trust 78,021 5,341 72,680 62,166 6.85 4.03
RFR The Rotherham NHS Foundation Trust 77,929 3,001 74,908 71,690 3.88 4.97
RJR Countess of Chester Hospital NHS Foundation Trust 77,873 14,195 63,668 54,593 18.24 4.02
RFS Chesterfield Royal Hospital NHS Foundation Trust 77,856 8,251 69,592 62,471 10.61 4.70
RTK Ashford and St Peter's Hospitals NHS Trust 76,917 19,201 57,705 54,980 24.98 5.59
RTP Surrey and Sussex Healthcare NHS Trust 76,289 4,756 71,338 64,308 6.49 4.22
RJ6 Mayday Healthcare NHS Trust 76,062 17,555 58,358 51,999 23.28 4.90
RA9 South Devon Healthcare NHS Foundation Trust 76,018 5,631 70,387 59,770 7.41 7.00
RAX Kingston Hospital NHS Trust 75,735 6,400 69,137 58,671 8.71 4.45
RQM Chelsea and Westminster Hospital NHS Foundation Trust 73,612 22,465 50,976 48,130 30.75 8.94
RFF Barnsley Hospital NHS Foundation Trust 72,290 8,314 63,915 54,122 11.59 5.33
RA2 Royal Surrey County Hospital NHS Trust 72,268 7,199 64,905 59,136 10.19 9.01
RNZ Salisbury NHS Foundation Trust 70,013 11,582 58,328 52,877 16.69 7.28
RD8 Milton Keynes Hospital NHS Foundation Trust 67,913 18,577 49,302 42,685 27.40 4.23
RJD Mid Staffordshire NHS Foundation Trust 67,644 5,927 61,717 56,492 8.76 4.19
RBK Walsall Hospitals NHS Trust 64,866 9,180 55,589 48,058 14.30 7.44
RNH Newham University Hospital NHS Trust 64,738 6,478 58,260 53,115 10.01 1.59
RQW The Princess Alexandra Hospital NHS Trust 64,080 5,778 58,163 55,201 9.23 5.87
RVY Southport and Ormskirk Hospital NHS Trust 63,471 1,797 61,646 54,926 2.88 4.05
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RGR West Suffolk Hospitals NHS Trust 63,242 8,309 54,933 47,546 13.14 4.57
RJ2 The Lewisham Hospital NHS Trust 59,122 11,198 47,848 45,320 19.07 7.30
RMP Tameside Hospital NHS Foundation Trust 58,050 1,391 56,648 49,679 2.42 3.22
RCF Airedale NHS Trust 57,362 5,197 52,147 45,489 9.09 3.74
RJC South Warwickshire General Hospitals NHS Trust 55,073 3,212 51,861 46,827 5.83 4.12
RAS The Hillingdon Hospital NHS Trust 54,496 4,425 50,041 47,786 8.17 2.87
RN5 Basingstoke and North Hampshire NHS Foundation Trust 54,441 3,859 50,534 45,956 7.18 3.88
RN7 Dartford and Gravesham NHS Trust 54,147 11,065 43,058 39,113 20.48 3.05
RJF Burton Hospitals NHS Trust 54,115 6,598 47,517 42,873 12.19 3.61
RBZ Northern Devon Healthcare NHS Trust 53,831 3,836 49,966 40,255 7.18 5.15
RAP North Middlesex University Hospital NHS Trust 53,669 7,191 46,419 35,715 13.51 3.59
RQX Homerton University Hospital NHS Foundation Trust 52,174 4,358 47,562 42,805 8.84 4.43
RFW West Middlesex University Hospital NHS Trust 51,550 5,134 46,410 38,903 9.97 5.26
RN1 Winchester and Eastleigh Healthcare NHS Trust 51,503 8,999 42,390 37,113 17.69 4.51
RC1 Bedford Hospital NHS Trust 51,497 8,157 43,257 39,143 16.00 6.23
RPY The Royal Marsden NHS Foundation Trust 51,482 1,329 50,103 50,103 2.68 6.42
RKE The Whittington Hospital NHS Trust 51,189 4,535 46,654 42,413 8.86 7.70
RCC Scarborough and North East Yorkshire Health Care NHS Trust 48,161 3,598 44,558 39,934 7.48 3.09
RBS Royal Liverpool Children's NHS Trust 47,033 7,116 39,913 35,265 15.14 32.43
RR7 Gateshead Health NHS Foundation Trust 46,978 3,027 43,951 37,444 6.44 2.24
RCD Harrogate and District NHS Foundation Trust 46,008 2,282 43,659 42,161 5.11 3.66
RA4 Yeovil District Hospital NHS Foundation Trust 45,977 3,310 42,204 34,619 8.21 4.78
RC3 Ealing Hospital NHS Trust 45,900 1,458 44,442 39,577 3.18 3.03
RLT George Eliot Hospital NHS Trust 43,694 3,611 40,083 36,600 8.26 4.78
RJN East Cheshire NHS Trust 42,061 4,743 37,318 33,596 11.28 3.37
RE9 South Tyneside NHS Foundation Trust 40,365 3,423 36,938 31,108 8.49 3.71
RQQ Hinchingbrooke Health Care NHS Trust 37,751 2,310 35,441 32,047 6.12 5.97
RA3 Weston Area Health NHS Trust 37,582 4,234 33,096 27,935 11.94 3.38
RLQ Hereford Hospitals NHS Trust 37,305 1,721 35,570 31,536 4.65 4.99
RQ3 Birmingham Children's Hospital NHS Foundation Trust 35,660 3,159 32,464 31,368 8.96 49.59
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RP4 Great Ormond Street Hospital For Children NHS Trust 33,746 5,197 28,549 26,041 15.40 71.42
RT3 Royal Brompton and Harefield NHS Trust 32,282 4,458 27,575 25,901 14.58 55.92
RM4 Trafford Healthcare NHS Trust 31,683 2,183 29,500 26,163 6.89 6.09
REP Liverpool Women's NHS Foundation Trust 29,012 638 28,374 28,351 2.20 0.62
RP6 Moorfields Eye Hospital NHS Foundation Trust 27,388 1,561 25,817 25,817 5.74 6.91
RCU Sheffield Children's NHS Foundation Trust 26,358 2,420 23,928 22,821 9.22 39.06
RGM Papworth Hospital NHS Foundation Trust 22,437 4,402 18,035 17,665 19.62 62.49
RBV Christie Hospital NHS Foundation Trust 22,424 4,274 18,145 17,945 19.08 21.47
RPC Queen Victoria Hospital NHS Foundation Trust 18,725 1,121 17,598 17,567 6.02 11.68
RLU Birmingham Women's NHS Foundation Trust 17,840 2,413 15,427 14,830 13.53 1.49
RRJ The Royal Orthopaedic Hospital NHS Foundation Trust 15,541 68 15,473 15,473 0.44 10.58
RET Walton Centre for Neurology and Neurosurgery NHS Trust 11,830 5,643 6,130 6,060 48.18 22.99
RAN Royal National Orthopaedic Hospital NHS Trust 11,203 54 11,142 11,130 0.54 20.49
RBQ The Cardiothoracic Centre - Liverpool NHS Trust 11,018 341 10,676 10,212 3.10 58.53
RL1 Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust 10,942 921 10,011 9,990 8.51 5.94
RBF Nuffield Orthopaedic Centre NHS Trust 9,881 457 9,424 9,372 4.63 4.02
REN Clatterbridge Centre for Oncology NHS Foundation Trust 4,264 986 3,190 3,182 25.19 8.36
RBB Royal National Hospital for Rheumatic Diseases NHS Foundation Trust 3,576 91 3,485 3,485 2.54 0.11
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Table 12: Equation 4 full results, OLS
Notes: Significance level: *** 1%, ** 5%, * 10%.
Cancer 0.186 *** 0.243 *** obesity 0.013 0.041 ***
BMT -0.089 -0.293 ** allergy 0.026 *** 0.030 ***
Haemophilia -0.200 * -0.232 ** diabetes -0.008 0.001
Womens -0.016 0.056 hypertens 0.047 -0.012
Spinal 0.269 *** -0.119 haemorr 0.081 ** 0.088 ***
Neurosciences 0.167 *** 0.108 histdis 0.020 * 0.021 **
Cystic fibrosis 0.330 *** 0.283 *** riskfact 0.001 -0.004
Renal -0.086 0.199 congmalf 0.051 *** 0.033
Intestinal failure -0.019 -0.004 risk_phys -0.007 0.045
Cardiology -0.059 -0.049 risk_psysoc 0.192 *** 0.164 ***
Cleft lip -0.014 0.047 tr_in_el 0.008 -0.061
Infectious diseases 0.202 *** 0.355 *** tr_in_nonel 0.160 ** 0.235 ***
Liver 0.063 -0.021 tr_out_el 0.140 *** 0.132 ***
Children 0.172 *** 0.183 *** tr_out_nonel 0.129 *** 0.110 ***
Dermatology -0.004 -0.013 die 0.072 *** 0.068 ***
Rheumatology 0.160 *** 0.127 * emerg -0.013 -0.017
Endocrinology 0.011 0.008 episodes 0.108 *** 0.116 ***
Respiratory -0.073 -0.041 dreg2 0.115 -0.035
Vascular diseases 0.173 ** 0.194 * dreg3 0.160 *** 0.065
Pain Management 0.217 2.168 *** dreg4 0.022 -0.015
Ear surgery 0.018 -0.088 dreg5 0.009 -0.041
Colorectal 0.212 *** 0.119 *** dreg6 0.068 -0.021
Orthopaedic 0.222 *** 0.007 dreg7 0.007 -0.069
Morbid obesity -0.010 -0.074 dreg8 0.044 0.050
Metabolic disorders 0.002 0.323 dreg9 0.055 -0.004
Ophthalmology 0.077 0.080 urban1 -0.003 0.002
Haemoglobinopathy 0.013 0.069 white1 0.015 ** -0.002
imd04c 0.000 -0.004 female1 0.599 0.184
imd04ed 0.000 0.000 male1 0.600 0.179
imd04hd -0.009 0.002 age 0.085 0.000
imd04hs 0.000 0.000 age2 -0.002 0.000
imd04i 0.090 ** 0.042 age3 0.000 * 0.000
imd04ia -0.047 * 0.053 femage -0.086 -0.002
imd04ic -0.078 *** -0.050 femage2 0.002 0.000
imd04le 0.000 0.000 femage3 0.000 * 0.000
imd04rk 0.000 *** 0.000 malage -0.087 -0.003
pregnancy 0.079 *** 0.077 *** malage2 0.002 0.000
drug -0.001 0.001 malage3 0.000 * 0.000
alcohol -0.041 *** -0.036 *** _cons 0.260 0.689 ***
smoke -0.008 -0.009 N 12,154,599 12,971,384
b/signif b/signifb/signif
2008-2009 2009-2010
b/signif
2008-2009 2009-2010
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Table 13: Equation 4 full results, GLM
Notes: Significance level: *** 1%, ** 5%, * 10%.
Cancer 0.194 *** 0.268 *** obesity 0.026 0.055 ***
BMT -0.025 -0.034 allergy 0.024 ** 0.030 ***
Haemophilia -0.163 -0.220 diabetes -0.018 0.000
Womens -0.002 0.062 hypertens 0.056 -0.022 **
Spinal 0.257 *** 0.126 * haemorr 0.071 ** 0.082 ***
Neurosciences 0.187 *** 0.184 *** histdis 0.020 0.036 ***
Cystic fibrosis 0.290 *** 0.255 *** riskfact -0.012 -0.003
Renal -0.091 0.216 congmalf 0.058 *** 0.045 **
Intestinal failure -0.023 -0.010 risk_phys 0.004 0.065 **
Cardiology 0.059 * 0.058 risk_psysoc 0.175 *** 0.162 ***
Cleft lip 0.003 0.049 tr_in_el 0.012 -0.004
Infectious diseases 0.183 *** 0.290 *** tr_in_nonel 0.157 *** 0.174 ***
Liver 0.075 0.084 ** tr_out_el 0.122 *** 0.117 ***
Children 0.216 *** 0.212 *** tr_out_nonel 0.129 *** 0.118 ***
Dermatology 0.016 -0.012 die 0.073 *** 0.072 ***
Rheumatology 0.197 *** 0.292 *** emerg -0.023 -0.033 *
Endocrinology 0.050 0.065 episodes 0.106 *** 0.116 ***
Respiratory -0.012 0.012 dreg2 0.109 -0.039
Vascular diseases 0.164 *** 0.241 *** dreg3 0.14 *** 0.053
Pain Management 0.209 1.226 *** dreg4 0.033 0.016
Ear surgery 0.084 0.099 dreg5 -0.017 -0.069
Colorectal 0.200 *** 0.125 *** dreg6 0.081 * 0.011
Orthopaedic 0.227 *** 0.158 *** dreg7 -0.021 -0.104 *
Morbid obesity -0.042 -0.109 dreg8 0.03 0.003
Metabolic disorders 0.025 0.342 dreg9 0.08 ** 0.033
Ophthalmology 0.095 0.081 urban1 0.005 0.011
Haemoglobinopathy 0.002 0.073 white1 0.008 -0.011
imd04c 0.021 * 0.007 female1 0.431 * 0.063
imd04ed 0.000 0.000 male1 0.434 * 0.056
imd04hd -0.022 0.000 age 0.07 * -0.015
imd04hs 0.001 0.000 age2 -0.002 ** 0.000
imd04i -0.075 -0.027 age3 0 ** 0.000
imd04ia 0.104 ** 0.119 * femage -0.071 * 0.014
imd04ic -0.014 0.025 femage2 0.002 ** 0.000
imd04le -0.001 * 0.000 femage3 0 ** 0.000
imd04rk 0.000 0.000 malage -0.071 ** 0.014
pregnancy 0.057 * 0.053 ** malage2 0.002 ** 0.000
drug -0.009 -0.012 malage3 0 ** 0.000
alcohol -0.051 *** -0.049 *** _cons -0.63 *** -0.240
smoke -0.005 0.002 N 12154599 12,971,384
2008-2009 2009-2010 2008-2009 2009-2010
b/signif b/signif b/signif b/signif
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Table 14: Variables label and definition
Variable name Description
imd04c Index of Multiple Deprivation: Crime
imd04ed Index of Multiple Deprivation: Education, Skills and training
imd04hd Index of Multiple Deprivation: Health Deprivation and Disability
imd04hs Index of Multiple Deprivation: Barriers to Housing and Services
imd04i Index of Multiple Deprivation: Income deprivation
imd04ia Index of Multiple Deprivation:Income Deprivation Affecting Older People
imd04ic Index of Multiple Deprivation: Income Deprivation Affecting Children
imd04le Index of Multiple Deprivation: Living Environment
imd04rk Index of Multiple Deprivation: Overall ranking
pregnancy =1, One of the patient diagnosis is: pregnancy,childbirth or puerperium
drug =1, Patient is drug user or drug dependent
alcohol =1, Patient is alcohol user or alcohol dependent
smoke =1, Patient is tobacco user or tobacco dependent
obesity =1, Patient with obesity problems
allergy =1, Patient with personal history of allergy
diabetes =1, Patient with diabetes problems
hypertens =1, Patient with hypertension problems
haemorr =1, Patient with haemorrage/coagulation problems
histdis =1, Patient with personal history of diseases
riskfact =1, Patient with other lifestyle risk factors
congmalf =1, Patient with congenital malformations
risk_phys =1, Patient exposed to physical risk factors
risk_psysoc =1, Patient with problems related to psychosocial circumstances
tr_in_el =1, Patient transferred from an eligible provider
tr_in_nonel =1, Patient transferred from a non-eligible provider
tr_out_el =1, Patient transferred to an eligible provider
tr_out_nonel =1, Patient transferred to a non-eligible provider
die =1, Patient died
emerg =1, Patient admitted as emergency
episodes Number of episodes in the spell
East of England =1, Region of treatment: East of England
London =1, Region of treatment: London
North-East =1, Region of treatment: North-East
North-West =1, Region of treatment: North-West
South-East =1, Region of treatment: South-East
South-West =1, Region of treatment: South-West
West Midlands =1, Region of treatment: West Midlands
Yorkshire =1, Region of treatment: Yorkshire
urban1 =1, Urban area
white1 =1, ethnicity is white
female1 =1, Patient is female
male1 =1, Patient is male
age Patient age at the beginning of the spell
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age2 Squared patient age
age3 Cubic power of patient age
femage Interaction: Age*Female
femage2 Interaction: Squared age*Female
femage3 Interaction: Cubic age*Female
malage Interaction: Age*Male
malage2 Interaction: Squared age*Male
malage3 Interaction: Cubic age*Male
